Source: Eur Respir J, 57 (3) 2003111; 10.1183/13993003.03111-2020
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Spyros A. Papiris, Demosthenes Bouros, Katerina Markopoulou, Lykourgos Kolilekas, Andriana I. Papaioannou, Vasilios Tzilas, Argyrios Tzouvelekis, Eva Fouka, Despoina Papakosta, Zoe Daniil, Paschalis Steiropoulos, Athina Gogali, Ilias C. Papanikolaou, Areti Xyfteri, Aggeliki Haritou, Ioanna Korbila, Ioannis P. Tomos, Stylianos Loukides, Rita Bellelli, Georgia Kounti, Christina Rampiadou, Theodoros Karampitsakos, Ilias Dimeas, Paraskevi Kirgou, Andromachi Bompoki, Eirini Vasarmidi, Konstantinos Loverdos, Elvira-Markela Antonogiannaki, Myrto Blizou, Evangelos Bouros, Konstantinos Kagouridis, Maria Maniati, Anna Karakatsani, Katerina M. Antoniou, Effrosyni D. Manali. Early COVID-19 lockdown in Greece and idiopathic pulmonary fibrosis: a beneficial “impact” beyond any expectation. Eur Respir J, 57 (3) 2003111; 10.1183/13993003.03111-2020

Member's Comments

No comment yet.

Related content which might interest you: Mortality benefit with antifibrotics in idiopathic pulmonary fibrosis: real world evidence or bias? Source: Eur Respir J, 57 (3) 2004562; 10.1183/13993003.04562-2020 Year: 2021 Real-life experience with pirfenidon in idiopathic pulmonary fibrosis: Does early treatment start predict better therapy adherence? Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Pirfenidone in idiopathic pulmonary fibrosis (IPF): Early single centre Irish experience Source: Annual Congress 2012 - Diffuse parenchymal lung disease III Year: 2012 Changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcomes Source: Eur Respir Rev 2012; 21: 161-167 Year: 2012 Economic consequences of idiopathic pulmonary fibrosis in Denmark Source: ERJ Open Res, 4 (2) 00045-2017; 10.1183/23120541.00045-2017 Year: 2018 Historical eye on idiopathic pulmonary fibrosis: redefining the mortality scenario. Source: Virtual Congress 2020 – New clinical insights into idiopathic pulmonary fibrosis Year: 2020 The burden of idiopathic pulmonary fibrosis reported by patients and carers in Ireland Source: International Congress 2015 – IPF: clinical aspects Year: 2015 Protocol for long-term effect of pulmonary rehabilitation under nintedanib in idiopathic pulmonary fibrosis Source: ERJ Open Res, 7 (3) 00321-2021; 10.1183/23120541.00321-2021 Year: 2021 The lived experience of idiopatic pulmonary fibrosis: A qualitative study Source: International Congress 2016 – Respiratory nursing research: opening new perspectives on patient experiences Year: 2016 Exercise training in idiopathic pulmonary fibrosis: is it of benefit? Source: Breathe 2016; 12: 130-138 Year: 2016 Pharmacotherapy for idiopathic pulmonary fibrosis: current landscape and future potential Source: Eur Respir Rev, 26 (145) 170071; 10.1183/16000617.0071-2017 Year: 2017 Pirfenidone treatment in idiopathic pulmonary fibrosis: too much of a great expectation Source: Eur Respir J 2012; 40: 794-795 Year: 2012 Who and what should we rely on in early diagnosis of idiopathic pulmonary fibrosis? Source: Eur Respir J 2013; 41: 249-250 Year: 2013 The increasing mortality of idiopathic pulmonary fibrosis: fact or fallacy? Source: Eur Respir J, 51 (1) 1702420; 10.1183/13993003.02420-2017 Year: 2018 Who and what should we rely on in early diagnosis of idiopathic pulmonary fibrosis? Source: Eur Respir J 2013; 41: 250-251 Year: 2013 The development of a measure to better understand patient experiences with pirfenidone and nintedanib for the treatment of idiopathic pulmonary fibrosis (IPF) Source: International Congress 2016 – IPF: from pathogenesis to treatment I Year: 2016 The epidemiologic features and the patterns of medical resource use in idiopathic pulmonary fibrosis (IPF) in Korea Source: International Congress 2015 – IPF: clinical aspects Year: 2015 Idiopathic pulmonary fibrosis: recent milestones in disease management Source: Eur Respir Rev 2012; 21: 140 Year: 2012 Effects of short-term pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis Source: Eur Respir J 2006; 28: Suppl. 50, 628s Year: 2006 Idiopathic pulmonary fibrosis: does smoking status influence outcome? Source: Eur Respir J 2006; 28: Suppl. 50, 830s Year: 2006